Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by MYSTICALon Apr 22, 2014 10:45am
390 Views
Post# 22476258

Major M&A this morning

Major M&A this morningCanadian drug company Valeant Pharmaceutical International Inc. (TSX: T.VRX, Stock Forum) has teamed with Bill Ackman's Pershing Square Capital Management in a cash and stock bid worth around $40 billion for Botox maker Allergan Inc. (NYSE: AGN, Stock Forum). Under the buyout offer Allergan shareholders would receive $48.30 in cash and 0.83 Valeant share for each share of Allergan. Valeant said it expected the cash portion of the deal to be at least US$15 billion. In a separate filing, Pershing Square said it owns a 9.7 per cent stake in Allergan worth $4.1 billion. Valeant shares gained $6.35 to $145.11. Swiss pharmaceutical giant Novartis AG is buying GlaxoSmithKline plc's cancer-drug business for US$14.5 billion, plus up to US$1.5 billion more if certain milestones are met, and to divest most of its vaccines business to GSK for US$7.1 billion, plus royalties. Separately, Novartis said it will sell off its animal health division to U.S.-based Eli Lilly & Co. for about US$5.4 billion. Novartis shares gained $1.27 to US$86.73 Read more at https://www.stockhouse.com/news/market-updates/2014/04/22/stocks-up-early-trading-amid-major-pharmaceutical-deal-making-solid-cp-t-cp#A6twygTQR8E7Kfhv.99
Bullboard Posts